Alnylam Pharmaceuticals (NASDAQ: ALNY) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Alnylam Pharmaceuticals to related businesses based on the strength of its dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and profitability.

Volatility and Risk

Alnylam Pharmaceuticals has a beta of 2.97, suggesting that its stock price is 197% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals’ rivals have a beta of 1.56, suggesting that their average stock price is 56% more volatile than the S&P 500.

Valuation and Earnings

This table compares Alnylam Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alnylam Pharmaceuticals $47.16 million -$410.10 million -23.55
Alnylam Pharmaceuticals Competitors $217.29 million -$39.39 million -65.63

Alnylam Pharmaceuticals’ rivals have higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Alnylam Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alnylam Pharmaceuticals -664.70% -46.94% -35.58%
Alnylam Pharmaceuticals Competitors -4,556.64% -563.40% -43.46%

Institutional and Insider Ownership

88.4% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.3% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Alnylam Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alnylam Pharmaceuticals 3 3 14 1 2.62
Alnylam Pharmaceuticals Competitors 537 2426 6652 128 2.65

Alnylam Pharmaceuticals presently has a consensus price target of $129.40, indicating a potential upside of 4.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.83%. Given Alnylam Pharmaceuticals’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals has less favorable growth aspects than its rivals.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company’s lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.